Pharmacotherapeutics in the Critically Ill COVID-19 Patients
Malaysian Journal of Medicine and Health Sciences
; 18(1):316-323, 2022.
Article
in English
| Scopus | ID: covidwho-1695178
ABSTRACT
Pharmacotherapeutics are being repurposed and used as off-label at various stages of COVID-19 infection. Clinical trials are being initiated or are ongoing to investigate the effectiveness and safety of these pharmacotherapeutics. This review article outlines the current pharmacotherapeutics and the controversies surrounding their use. The pharmacotherapeutics that were discussed are hydroxychloroquine, favipiravir, lopinavir/ritonavir, remdesivir, interferons, tocilizumab, and steroids. We also discussed the special consideration for pharmacotherapeutics in COVID-19 infection. No pharmacotherapeutics have been found to be effective and approved for the treatment of COVID-19 infection. However, there are clinical trials that have eliminated the possibilities of use of some pharmacotherapeutics while others had shown promising preliminary results of its use. © 2022 UPM Press. All rights reserved.
Search on Google
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Malaysian Journal of Medicine and Health Sciences
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS